patient unsuitable for MRI scanning (e.g. metal implants, pacemaker, claustrophobia, hypersensitivity to DCE-MRI contrast material)

brain metastases

clinically significant ascites

active bleeding, bleeding diathesis, oral anti-vitamin K medication (other than low dose coumarin) or history of coagulation disorders

radiation therapy within 3 weeks, or anti-neoplastic therapy \<30 days prior to first dose of study drug

chronic therapy with systemic steroids or another immunosuppressive agent \<2 weeks prior to first dose of study drug

treated with bevacizumab in last regimen of systemic therapy

A Dose-finding Study of RO5323441 in Patients With Metastatic Treatment-Refractory Colorectal or Ovarian Cancer